Treatment trial of oxiracetam in Alzheimer's disease

Arch Neurol. 1992 Nov;49(11):1135-6. doi: 10.1001/archneur.1992.00530350049018.


Twenty-four carefully assessed patients with probable Alzheimer's disease were enrolled in a double-blind, placebo-controlled treatment study of oxiracetam, a nootropic agent reported to improve memory performance in patients with dementia. A broad battery of neuropsychological tests failed to reveal any improvement in the treated group or in any treated patient when individual test scores were analyzed. These findings indicate that oxiracetam is ineffective in reducing cognitive impairment due to Alzheimer's disease.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Alzheimer Disease / complications
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / psychology
  • Cognition Disorders / drug therapy
  • Cognition Disorders / etiology
  • Double-Blind Method
  • Humans
  • Neuropsychological Tests
  • Placebos
  • Pyrrolidines / administration & dosage*


  • Placebos
  • Pyrrolidines
  • oxiracetam